In this explorative investigation we applied a quantitative metabolomics profiling to human NSCLC isogenic cell lines harboring G12C or WT KRAS isoforms and to their derived tumors implanted in immunodeficent mice, in order to decipher whether and how much the cancer cell metabolic findings obtained in vitro could be translated into the metabolism of the whole tumor. This evidence concerns the gene KRAS and non-small cell lung carcinoma.